Bacteriophages and their potential for treatment of metabolic diseases

Journal of Diabetes, Journal Year: 2024, Volume and Issue: 16(11)

Published: Nov. 1, 2024

Abstract Recent advances highlight the role of gut virome, particularly phageome, in metabolic disorders such as obesity, type 2 diabetes mellitus, dysfunction‐associated fatty liver disease, and cardiovascular diseases, including hypertension, stroke, coronary heart hyperlipidemia. While alterations bacteria are well‐documented, emerging evidence suggests that changes viruses also contribute to these disorders. Bacteriophages, most abundant viruses, influence bacterial populations through their lytic lysogenic cycles, potentially modulating ecosystem pathways. Phage therapy, previously overshadowed by antibiotics, is experiencing renewed interest due rising antibiotic resistance. It offers a novel approach precisely edit microbiota, with promising applications diseases. In this review, we summarize recent discoveries about virome disease patients, review preclinical clinical studies phage therapy on diseases well breakthroughs currently faced problems concerns. image

Language: Английский

The Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2882 - 2882

Published: March 22, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition wherein excessive fat accumulates in the liver, leading to inflammation and potential damage. In this narrative review, we evaluate tissue microbiota, how they arise their constituent microbes, role of intestinal hepatic microbiota MASLD. The history bacteriophages (phages) occurrence part causation MASLD, conversely, "phage therapy" for antibiotic resistance, obesity, are all described. metabolism bile acids dietary tryptophan histidine defined, together with impacts individual metabolites on MASLD pathogenesis. Both periodontitis dysbiosis may cause microorganisms involved these processes discussed. Novel treatment opportunities involving exist include fecal transplantation, probiotics, prebiotics, synbiotics, supplements, intermittent fasting, phages or holins endolysins. Although FDA yet approve phage therapy clinical use, there multiple FDA-approved trials, represent new horizon future

Language: Английский

Opportunities for Helicobacter pylori Eradication beyond Conventional Antibiotics

Microorganisms, Journal Year: 2024, Volume and Issue: 12(10), P. 1986 - 1986

Published: Sept. 30, 2024

(